These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32004442)

  • 1. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
    Karakashev S; Fukumoto T; Zhao B; Lin J; Wu S; Fatkhutdinov N; Park PH; Semenova G; Jean S; Cadungog MG; Borowsky ME; Kossenkov AV; Liu Q; Zhang R
    Cancer Cell; 2020 Feb; 37(2):157-167.e6. PubMed ID: 32004442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors.
    Karakashev S; Zhang R
    Mol Cell Oncol; 2020; 7(4):1760675. PubMed ID: 32944622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells.
    Hatchi E; Livingston DM
    Cancer Cell; 2020 Feb; 37(2):139-140. PubMed ID: 32049041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
    Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
    Lin S; Tian J; He Q; Yang M; Chen Z; Belogurov AA; Li X; Zhang F; Liu Y; Chen G
    Dis Markers; 2022; 2022():7243146. PubMed ID: 36267463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
    Reilly NM; Yard BD; Pittman DL
    Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
    Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
    Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor.
    Philip KT; Dutta K; Chakraborty S; Patro BS
    Int J Biochem Cell Biol; 2023 Aug; 161():106443. PubMed ID: 37392863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
    Chen L; Hou J; Zeng X; Guo Q; Deng M; Kloeber JA; Tu X; Zhao F; Wu Z; Huang J; Luo K; Kim W; Lou Z
    Clin Transl Med; 2021 Mar; 11(3):e341. PubMed ID: 33784003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermia synergistically enhances antitumor efficacy of PARP inhibitor through impacting homologous recombination repair and oxidative stress in vitro.
    Wu Q; Wei M; Yao L; Cheng X; Lu W; Xie X; Li X
    Biochem Biophys Res Commun; 2022 Sep; 619():49-55. PubMed ID: 35738064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair.
    Li F; Sarangi P; Iyer DR; Feng H; Moreau L; Nguyen H; Clairmont C; D'Andrea AD
    Cell Rep; 2022 Aug; 40(9):111297. PubMed ID: 36044844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
    Metzger MJ; Stoddard BL; Monnat RJ
    DNA Repair (Amst); 2013 Jul; 12(7):529-34. PubMed ID: 23684799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
    Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
    Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance.
    Fujita H; Ikeda M; Ui A; Ouchi Y; Mikami Y; Kanno SI; Yasui A; Tanaka K
    Oncogene; 2022 May; 41(19):2706-2718. PubMed ID: 35393543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition.
    Lin X; Soni A; Hessenow R; Sun Y; Mladenov E; Guberina M; Stuschke M; Iliakis G
    Radiother Oncol; 2024 Nov; 200():110475. PubMed ID: 39147034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.